NCT05275660View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 9, 2021

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Healthy
Interventions
DRUG

HFB30132A

Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.

OTHER

Placebo

Participants randomized to placebo will receive the same volume of solution as participants on active treatment.

Trial Locations (1)

Unknown

Huashan Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

HiFiBiO Therapeutics

INDUSTRY

NCT05275660 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults | Biotech Hunter | Biotech Hunter